Director Jan De Witte of ResMed Inc filed a Form 144 notice on November 17, 2026, disclosing a proposed sale of 429 shares of ResMed common stock under Rule 144 of the Securities Act of 1933.
Key Highlights
- Seller: Jan De Witte, identified in the filing as a Director of ResMed Inc.
- Shares proposed for sale: 429 shares of ResMed common stock, with an aggregate market value of $101,673.00 as stated in the filing.
- Acquisition: The 429 shares were acquired on November 11, 2026, through restricted stock vesting from the issuer, with payment characterized as compensation.
- Approximate sale date: November 17, 2026, through Fidelity Brokerage Services LLC on the NYSE.
- Rule 10b5-1 plan: The filing indicates a plan adoption date of August 19, 2026.
- Shares outstanding: The filing reports 140,657,071 shares of ResMed common stock outstanding.
- Prior sales: The filing states nothing to report for securities sold during the past three months.
ResMed Director Jan De Witte Discloses Proposed Restricted Stock Sale
According to the Form 144 notice filed with the U.S. Securities and Exchange Commission, Jan De Witte, a Director of ResMed Inc (NYSE:RMD), proposed to sell 429 shares of the company's common stock. The filing lists Fidelity Brokerage Services LLC, located at 900 Salem Street, Smithfield, Rhode Island 02917, as the broker for the transaction, with an approximate sale date of November 17, 2026, on the NYSE.
The filing discloses that the 429 shares were acquired on November 11, 2026, through a restricted stock vesting transaction from the issuer, with the nature of payment described as compensation. The aggregate market value of the shares to be sold is listed as $101,673.00. The notice was signed by Jennifer Ruchti as a duly authorized representative of Fidelity Brokerage Services LLC, acting as attorney-in-fact for Jan De Witte.
The filing also indicates that De Witte adopted a written trading plan under Rule 10b5-1 on August 19, 2026. Under that rule, by indicating the plan adoption date, the signatory represents that the required statutory representation was made as of that date. No securities sales by De Witte during the prior three months were reported in the filing.
What Was Disclosed
ResMed Director Jan De Witte filed a Form 144 on November 17, 2026, proposing to sell 429 shares of ResMed common stock with an aggregate market value of $101,673.00, acquired via restricted stock vesting on November 11, 2026, under a Rule 10b5-1 plan adopted August 19, 2026.





Please wait processing your request...